• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors".

作者信息

Kim Sung-Hyun, Kim Dong-Wook

机构信息

Dong-A University Medical Center, Busan, South Korea.

Seoul St. Mary's Hospital, Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea

出版信息

Haematologica. 2015 Mar;100(3):e120-1. doi: 10.3324/haematol.2014.123232.

DOI:10.3324/haematol.2014.123232
PMID:25740109
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4349295/
Abstract
摘要

相似文献

1
Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors".关于“达沙替尼在对BCR-ABL1酪氨酸激酶抑制剂耐药或不耐受的慢性期慢性髓性白血病患者中的疗效和安全性”的评论
Haematologica. 2015 Mar;100(3):e120-1. doi: 10.3324/haematol.2014.123232.
2
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.达沙替尼在对BCR-ABL1酪氨酸激酶抑制剂耐药或不耐受的慢性期慢性髓性白血病患者中的疗效和安全性。
Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4.
3
Radotinib in the treatment of chronic phase chronic myeloid leukemia patients.来那度胺治疗慢性期慢性髓性白血病患者。 （注：原文中药物名称有误，正确的应该是“Rilotumumab”，翻译为“来那度胺”，按照正确药物名翻译后的译文供你参考，实际需按照正确原文准确翻译。这里按照你提供的错误原文翻译为：拉多替尼治疗慢性期慢性髓性白血病患者 ）
Haematologica. 2015 Jan;100(1):e39. doi: 10.3324/haematol.2014.117846.
4
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.根据欧洲白血病网络2013标准评估伊马替尼耐药或不耐受的慢性髓性白血病慢性期患者临床疗效及安全性的前瞻性分析。
Eur J Haematol. 2015 Dec;95(6):558-65. doi: 10.1111/ejh.12536. Epub 2015 Mar 25.
5
Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.一线达沙替尼治疗新诊断慢性期慢性髓性白血病的临床疗效与安全性以及BCR-ABL1转录本下降速度与实现分子反应的相关性：顺天堂山梨合作研究组报告
Oncology. 2018;94(2):85-91. doi: 10.1159/000481945. Epub 2017 Nov 18.
6
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.三期临床试验（RERISE 研究）：雷替尼与伊马替尼治疗新诊断慢性期慢性髓性白血病的疗效和安全性比较结果。
Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22.
7
BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.用于治疗慢性粒细胞白血病的BCR-ABL1酪氨酸激酶抑制剂
J Oncol Pharm Pract. 2018 Sep;24(6):433-452. doi: 10.1177/1078155217710553. Epub 2017 Jun 4.
8
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.应用酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病中 BCR-ABL1 激酶结构域的分子分析：长崎 CML 研究组的研究。
Leuk Res. 2014 Jan;38(1):76-83. doi: 10.1016/j.leukres.2013.10.022. Epub 2013 Nov 5.
9
Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.达沙替尼治疗慢性期慢性髓性白血病患者中 BCR-ABL1 转录本的快速减少可预测深度分子反应。
Eur J Haematol. 2018 Jan;100(1):27-35. doi: 10.1111/ejh.12969. Epub 2017 Oct 16.
10
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.新型酪氨酸激酶抑制剂与伊马替尼在不同风险组慢性期慢性髓性白血病一线治疗中的疗效比较：八项随机试验的系统评价和荟萃分析
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94. doi: 10.1016/j.clml.2016.03.003. Epub 2016 Mar 30.

引用本文的文献

1
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.达沙替尼及其在慢性期慢性髓性白血病患者中的临床潜力：最新进展
Ther Adv Hematol. 2017 Sep;8(9):237-243. doi: 10.1177/2040620717719851. Epub 2017 Jul 25.

本文引用的文献

1
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.达沙替尼在对BCR-ABL1酪氨酸激酶抑制剂耐药或不耐受的慢性期慢性髓性白血病患者中的疗效和安全性。
Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4.
2
Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.达沙替尼与伊马替尼治疗新诊断慢性期慢性髓性白血病DASISION试验东亚亚组的疗效与安全性
Leuk Lymphoma. 2014 Sep;55(9):2093-100. doi: 10.3109/10428194.2013.866663. Epub 2014 Mar 12.
3
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.慢性髓性白血病（CML）药物的价格反映了癌症药物的不可持续价格：从一大群 CML 专家的角度来看。
Blood. 2013 May 30;121(22):4439-42. doi: 10.1182/blood-2013-03-490003. Epub 2013 Apr 25.
4
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.尼洛替尼治疗伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者有效：24 个月随访结果。
Blood. 2011 Jan 27;117(4):1141-5. doi: 10.1182/blood-2010-03-277152. Epub 2010 Nov 22.
5
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.达沙替尼在亚洲和非亚洲慢性髓性白血病患者中的临床特征
Int J Hematol. 2009 Jun;89(5):664-72. doi: 10.1007/s12185-009-0326-1. Epub 2009 May 20.
6
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.达沙替尼可使对伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者产生持久的细胞遗传学反应。
Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.
7
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.尼罗替尼（原AMN107）是一种高度选择性的BCR-ABL酪氨酸激酶抑制剂，对伊马替尼耐药和不耐受的慢性期费城染色体阳性慢性髓性白血病患者有效。
Blood. 2007 Nov 15;110(10):3540-6. doi: 10.1182/blood-2007-03-080689. Epub 2007 Aug 22.
8
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.达沙替尼在伊马替尼治疗失败后的慢性期慢性髓性白血病中可诱导显著的血液学和细胞遗传学反应。
Blood. 2007 Mar 15;109(6):2303-9. doi: 10.1182/blood-2006-09-047266. Epub 2006 Nov 30.